MetLife Investment Advisors LLC Has $2.50 Million Position in PerkinElmer, Inc. (NYSE:PKI)

MetLife Investment Advisors LLC decreased its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 1.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 31,810 shares of the medical research company’s stock after selling 402 shares during the period. MetLife Investment Advisors LLC’s holdings in PerkinElmer were worth $2,499,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Lindbrook Capital LLC bought a new stake in shares of PerkinElmer in the 4th quarter worth approximately $25,000. Citizens Financial Group Inc RI bought a new stake in shares of PerkinElmer in the 4th quarter worth approximately $32,000. Penserra Capital Management LLC bought a new stake in shares of PerkinElmer in the 4th quarter worth approximately $35,000. Financial Gravity Companies Inc. bought a new stake in shares of PerkinElmer in the 4th quarter worth approximately $49,000. Finally, Karp Capital Management Corp bought a new stake in shares of PerkinElmer in the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 96.37% of the company’s stock.

In other news, insider Prahlad R. Singh sold 3,289 shares of the stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $102.39, for a total transaction of $336,760.71. Following the transaction, the insider now directly owns 28,242 shares of the company’s stock, valued at approximately $2,891,698.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel R. Tereau sold 1,200 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $93.27, for a total value of $111,924.00. Following the completion of the sale, the insider now owns 5,839 shares of the company’s stock, valued at $544,603.53. The disclosure for this sale can be found here. Insiders have sold a total of 62,475 shares of company stock worth $5,910,744 over the last three months. Insiders own 1.80% of the company’s stock.

PKI stock traded up $0.56 during midday trading on Friday, hitting $94.15. The company’s stock had a trading volume of 721,415 shares, compared to its average volume of 604,739. The stock has a market capitalization of $10.44 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 2.05 and a beta of 1.25. PerkinElmer, Inc. has a 12 month low of $70.83 and a 12 month high of $103.00. The company has a current ratio of 1.60, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73.

PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Thursday, January 31st. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.02. The business had revenue of $756.35 million for the quarter, compared to analysts’ expectations of $746.15 million. PerkinElmer had a return on equity of 15.89% and a net margin of 8.56%. During the same period in the prior year, the firm posted $0.97 EPS. On average, research analysts predict that PerkinElmer, Inc. will post 4.03 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.07 per share. The ex-dividend date is Wednesday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. PerkinElmer’s payout ratio is 7.76%.

PKI has been the topic of a number of analyst reports. Desjardins reissued an “average” rating and issued a $45.00 price target on shares of PerkinElmer in a research report on Wednesday, January 16th. Morgan Stanley dropped their price target on PerkinElmer from $100.00 to $86.00 and set an “overweight” rating on the stock in a research report on Thursday, January 3rd. CIBC reissued an “average” rating and issued a $44.50 price target on shares of PerkinElmer in a research report on Thursday, January 10th. Zacks Investment Research cut PerkinElmer from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Finally, Piper Jaffray Companies boosted their price target on PerkinElmer to $104.00 and gave the stock an “overweight” rating in a research report on Friday, February 1st. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $85.06.

COPYRIGHT VIOLATION NOTICE: “MetLife Investment Advisors LLC Has $2.50 Million Position in PerkinElmer, Inc. (NYSE:PKI)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/perkinelmer-inc-pki-stake-lowered-by-metlife-investment-advisors-llc.html.

PerkinElmer Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Read More: Dividend

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.